The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Making optimal decisions in frontline treatment of CLL: fixed-duration vs continuous BTKi treatment
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on how to make optimal treatment decisions in the frontline treatment of chronic lymphocytic leukemia (CLL). She outlines the factors that can be used to guide therapeutic decisions, including mutational profile, comorbidity burden, age, concomitant medications, and patient preferences. Dr Scarfò highlights the ESMO guidelines, which suggest that fixed-duration BTK inhibitor (BTKi) treatment should be favored over continuous treatment when evidence of similar efficacy and tolerability is available. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are generally following the guidelines and there is currently an update of the ESMO guidelines that will be further updated, I suppose, in the next month. So the first layer of decision is actually based on the biomarker profile, meaning that we should assess patients for the presence of 17p deletion, TP53 mutation, and immunoglobulin gene mutation status. But then, provided that we are not using chemoimmunotherapy anymore, luckily enough, we can further tailor treatment decisions based on one side on the comorbidity burden, the age, the concomitant medications, and on the other side, of course, we should take into account patient preferences...
We are generally following the guidelines and there is currently an update of the ESMO guidelines that will be further updated, I suppose, in the next month. So the first layer of decision is actually based on the biomarker profile, meaning that we should assess patients for the presence of 17p deletion, TP53 mutation, and immunoglobulin gene mutation status. But then, provided that we are not using chemoimmunotherapy anymore, luckily enough, we can further tailor treatment decisions based on one side on the comorbidity burden, the age, the concomitant medications, and on the other side, of course, we should take into account patient preferences. So I dare say that the general principle of the guidelines is that whenever we have available evidence of similar efficacy and similar or even better tolerability, we should favor fixed-duration treatments compared to continuous general BTKi treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
